Skip to main content

Spineway : First-quarter 2026 revenue

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Ecully, April 30, 2026 – 6:00 p.m.

First-quarter 2026 revenue

  • High order volume
  • Slower-than-expected normalization of supply chains
  • 2026: growth trajectory confirmed
In thousands of euros20262025Change

as a %

Q1 revenue2,1762,828-23%

Unaudited consolidated data

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.2 million in the first quarter of 2026.

Following strong growth in the fourth quarter of 2025 (+38%), the slowdown observed in the first quarter of 2026 will not undermine the Group’s momentum. It is mainly attributable to delays in regulatory approvals in certain regions and supply delays from subcontractors facing increased demand. These challenges have been identified, contained, and are being resolved.

International export sales (excluding Europe) were mixed:

In Asia, business remains solid, with revenue up 3.7% and with growth prospects in Vietnam and Australia.

In the Middle East, business is at a temporary standstill against adverse geopolitical backdrop.

In Latin America, revenue came in €0.4 million below the previous year, impacted by a slower-than-anticipated ramp-up in deliveries. The Group continues to expand its distribution network in this high-potential region (particularly in Mexico and Brazil), with a view to achieving critical mass.

In France, the domestic market remains resilient, with stable revenue supported by prioritized inventory management while in Europe revenue was slightly down.

In a structurally favorable healthcare environment, Spineway continues to expand, notably through the intensification of its multi-year regulatory approval program. With a robust order backlog, the Group expects the lag between orders and revenue to gradually normalize from the second half of 2026 onwards. This will help offset the quarterly volatility associated with the current growth phase.

Next event:

July 30, 2026 – H1 2026 revenue and results

About Spineway

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and more than 70% of its revenue comes from exports.

Spineway is eligible for the PEA-PME (equity savings plans for SMEs)

Listing venue: Euronext Growth Paris
ISIN: FR001400N2P2
Ticker: ALSPW

Find out all about Spineway at www.spineway.com

Contacts:

Spineway
Shareholder-services line
Available Tuesday through Thursday (10 a.m.-12 midday)
+33 (0)806 706 060

Aelium
Investor relations
Isabelle Desmottes                                      
spineway@aelium.fr

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.